In a phase 1 trial, a PYY analogue (Y14 peptide) administered subcutaneously at 7- to 14-days intervals was safe and potentially efficacious (WL between 2.9 and 3.6 kg at 31 days, with a 3855% reduction in food intake vs
The choice of laxative should be individualised based on symptom severity, stool consistency, patient preference, and any co-existing medical conditions
Obesity and metabolic disorders have become a global health problem 1
At Regenerate Wellness, we offer holistic, whole-body solutions that enhance quality of life and overall health and wellness
Why physician-supervised weight loss matters Patients comparing weight-loss injections, online programs, and clinic-based care need more than a prescription
Campsite: Choquequirao Archaeological Centre